Indaptus Therapeutics to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
January 05, 2022 07:00 ET
|
Indaptus Therapeutics
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate...
Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer
January 03, 2022 07:00 ET
|
Indaptus Therapeutics
Seasoned Drug Developer Brings More Than Twenty Years of Medical Leadership and Clinical Oncology Experience On Track to Initiate Phase 1 Study of Decoy20 in 2022 NEW YORK, Jan. 03, 2022 (GLOBE...
Indaptus Therapeutics Appoints Mark Gilbert, M.D., to Board of Directors
December 01, 2021 08:00 ET
|
Indaptus Therapeutics
NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces the appointment of Mark Gilbert, M.D., to its Board of...
Indaptus Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021 07:00 ET
|
Indaptus Therapeutics
NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces financial results for the third quarter ended September 30, 2021...
Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent
September 15, 2021 07:00 ET
|
Indaptus Therapeutics
NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the United States Patent and Trademark Office has issued a...